Loading…

Resistance of Sézary cells to TNF-α-induced apoptosis is mediated in part by a loss of TNFR1 and a high level of the IER3 expression

:  Failure to execute an apoptotic programme is one of the critical steps and a common mechanism promoting tumorogenesis. Immediate early responsive gene 3 (IER3) has been shown to be upregulated in several cancers. IER3 is a stress‐induced gene, which upregulation leads to reduction in production o...

Full description

Saved in:
Bibliographic Details
Published in:Experimental dermatology 2012-04, Vol.21 (4), p.287-292
Main Authors: Akilov, Oleg E., Wu, Mei X., Ustyugova, Irina V., Falo Jr, Louis D., Geskin, Larisa J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary::  Failure to execute an apoptotic programme is one of the critical steps and a common mechanism promoting tumorogenesis. Immediate early responsive gene 3 (IER3) has been shown to be upregulated in several cancers. IER3 is a stress‐induced gene, which upregulation leads to reduction in production of reactive oxygen species (ROS) protecting malignant cells from apoptosis. We observed that malignant lymphocytes from patients with Sézary syndrome (SzS) were resistant to pro‐apoptotic dose of tumour necrosis factor‐α (TNF‐α). The aim of this study was to investigate the role of IER3 in the mechanism of such resistance. CD4+ CD26− lymphocytes from the peripheral blood of patients with SzS and healthy controls were negatively selected using CD4 and CD26 magnetic beads and analysed for expression of TNFR1, TNFR2, IER3 expression, and ROS production in response to TNF‐α at an apoptotic dose. Sézary cells with a higher level of IER3 expression retained their viability to TNF‐α. IER3 upregulation correlated with a decrease level of intracellular ROS and low TNFR1 expression on malignant cells. Targeting IER3 could be of interest for the development of future therapeutic strategies for patients with SzS.
ISSN:0906-6705
1600-0625
DOI:10.1111/j.1600-0625.2012.01452.x